Adcendo Raises $75M for ADC Cancer Drug Pipeline

Adcendo, a Copenhagen-based biotechnology firm, has successfully closed a substantial $75 million Series C funding round. This significant capital infusion, which was oversubscribed, is earmarked to accelerate the development of its innovative antibody-drug conjugate (ADC) pipeline targeting aggressive cancers with limited treatment options.

The financing was spearheaded by Jeito Capital, a prominent life sciences investment firm. A strong cohort of new investors joined the round, including Vida Ventures, Bpifrance, and EIFO. Demonstrating continued conviction in the company's vision, a robust group of existing backers also participated, reinforcing the strong investor confidence. These include RA Capital Management, TPG, OrbiMed, Venrock, Novo Holdings, and KKR-backed Dawn Biopharma, among others.

With this fresh capital, Adcendo plans to advance three key ADC programs through critical clinical development stages. The company is focused on pushing forward ADCE-T02, a Tissue Factor-targeting ADC currently undergoing a Phase I expansion study across various tumor types. Additionally, ADCE-D01, which targets uPARAP, is being evaluated for soft tissue sarcoma and related malignancies. The third program, ADCE-B05, involves an undisclosed target and is in the early stages of development for squamous cell carcinomas.

The antibody-drug conjugate market is experiencing rapid expansion, driven by advancements in targeted delivery mechanisms and potent payloads. This sector is projected to reach tens of billions of dollars in the coming years, with companies like Adcendo aiming to capture significant share by addressing unmet needs. Adcendo differentiates itself through a strategy that combines novel target identification with optimized linker-payload technologies and a data-centric approach to drug development.

In conjunction with the financing, Adcendo announced key additions to its Board of Directors. Ksenija Pavletic, representing lead investor Jeito Capital, and Rajul Jain from Vida Ventures will bring their extensive expertise to guide the company's strategic direction. This move underscores the investors' active engagement and belief in Adcendo's potential to deliver next-generation cancer therapies.

The oversubscribed nature of this Series C round highlights the market's positive reception to Adcendo's scientific approach and its promising clinical progress. The company's focus on developing first- and best-in-class ADCs positions it to address significant challenges in oncology, offering hope for patients with difficult-to-treat cancers. The successful fundraising provides a strong foundation for achieving upcoming data readouts and advancing its pipeline toward potential commercialization.